EMA Authorised: Liprolog (insulin lispro) — Eli Lilly Nederland B.V.

View source ↗

Summary

EMA authorised Liprolog (insulin lispro) for diabetes mellitus. The marketing authorisation holder is Eli Lilly Nederland B.V.; decision date 21 January 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Liprolog (insulin lispro)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Eli Lilly Nederland B.V.. Decision date: 21/01/2026